Dermatitis herpetiformis intolerant to dapsone in Aids

Area of Science:

• Dermatology
• Infectious Diseases
• Immunology

Background:

• Dermatitis herpetiformis is a chronic autoimmune blistering skin condition.
• Human Immunodeficiency Virus (HIV) infection and tuberculosis can complicate dermatological management.
• Dapsone, a common treatment for dermatitis herpetiformis, may not be tolerated by all patients.

Purpose of the Study:

• To describe a successful alternative management strategy for dermatitis herpetiformis in an immunocompromised patient.
• To evaluate the efficacy of a combination therapy including nicotinamide and indomethacin.

Main Methods:

• A case report of a 35-year-old male patient with Acquired Immunodeficiency Syndrome (AIDS) and pulmonary tuberculosis.
• Treatment involved oral nicotinamide (200 mg/day), oral indomethacin (75 mg/day), topical corticosteroids, and a gluten-free diet.
• Monitoring of skin lesions and patient tolerance to the therapeutic regimen.

Main Results:

• The patient showed successful resolution of dermatitis herpetiformis-like lesions.
• The combination therapy was well-tolerated, with no adverse effects reported.
• Significant improvement in skin condition was observed.

Conclusions:

• Nicotinamide and indomethacin, alongside topical steroids and a gluten-free diet, offer a viable alternative for managing dermatitis herpetiformis in dapsone-intolerant patients.
• This therapeutic approach may be particularly beneficial in immunocompromised individuals with co-existing infections.
• Further research is warranted to confirm the efficacy and safety of this treatment combination.